METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC)
Clinical trials for METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC) explained in plain language.
Never miss a new study
Get alerted when new METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC) trials appear
Sign up with your email to follow new studies for METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Tracking 500 Men's journey with new prostate cancer treatment
Disease control Not yet recruitingThis study follows 500 men in Germany with advanced prostate cancer that has spread but still responds to hormone therapy. Doctors will track how well the combination of darolutamide (a newer hormone-blocking drug) plus standard hormone therapy works in real-world settings over 5…
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC)
Sponsor: Bayer • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC
-
Radical surgery tested as new hope for men with widespread prostate cancer
Disease control Not yet recruitingThis study is testing whether surgically removing the prostate helps men with advanced prostate cancer that has already spread to other parts of the body. After 6 months of strong hormone-blocking drug therapy, patients whose scans show the cancer has quieted down will be randoml…
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC)
Phase: PHASE2 • Sponsor: Fudan University • Aim: Disease control
Last updated Mar 23, 2026 15:16 UTC